Mitral valve replacement for mitral stenosis: A 15-year single center experience  by Al Mosa, Alqasem F. et al.
P.O. Box 2925 Riyadh – 11461KSA
Tel: +966 1 2520088 ext 40151
Fax: +966 1 2520718
Email: sha@sha.org.sa
URL: www.sha.org.sa
FU
LL LEN
G
TH
 A
RTIC
LE
Disclosure: Authors have nothing to disclose with regard to commercial
support.
Received 1 October 2015; revised 2 February 2016; accepted 11 February
2016.
Available online 2 March 2016
⇑ Corresponding author at: Heart and Vascular Institute, Cleveland
Clinic, 9500 Euclid Ave/M41, Cleveland, Ohio, 44195, United States.
E-mail address: najmh@ccf.org (H.K. Najm).Mitral valve replacement for mitral stenosis:
A 15-year single center experience1016–7315  2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of King Saud University.
URL: www.ksu.edu.sa
http://dx.doi.org/10.1016/j.jsha.2016.02.007
Production and hosting by ElsevierAlqasem F. Al Mosa a, Aamir Omair b, Ahmed A. Arifi c, Hani K. Najm d,⇑aKing Saud bin Abdulaziz University for Health Sciences, College of Medicine, Riyadh
bKing Saud bin Abdulaziz University for Health Sciences, Medical Education, Riyadh
cCardiac Clinical Research, Cardiac Surgery, Cardiac Sciences, King Abdulaziz Cardiac Center, Ministry of National Guard, Riyadh
dHeart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave/M41, Cleveland, Ohio, 44195
a,b,c Saudi Arabia
d USAObjectives: Mitral valve replacement with either a bioprosthetic or a mechanical valve is the treatment of choice for
severe mitral stenosis. However, choosing a valve implant type is still a subject of debate. This study aimed to evaluate
and compare the early and late outcomes of mitral valve replacement [mechanical (MMV) vs. bioprosthetic (BMV)] for
severe mitral stenosis.
Methods: A retrospective cohort study was performed on data involving mitral stenosis patients who have under-
gone mitral valve replacement with either BMV (n = 50) or MMV (n = 145) valves from 1999 to 2012. Data were col-
lected from the patients’ records and follow-up through telephone calls. Data were analyzed for early and late
mortality, New York Heart Association (NYHA) functional classes, stroke, pre- and postoperative echocardiographic
findings, early and late valve-related complications, and survival. Chi-square test, logistic regression, Kaplan–Meier
curve, and dependent proportions tests were some of the tests employed in the analysis.
Results: A total of 195 patients were included in the study with a 30-day follow-up echocardiogram available for
190 patients (97.5%), while 103 (53%) were available for follow-up over the telephone. One patient died early post-
operatively; twelve patients died late in the postoperative period, six in the bioprosthesis group and six in the
mechanical group. The late mortality had a significant association with postoperative stroke (p < 0.001) and postop-
erative NYHA Classes III and IV (p = 0.002). Postoperative NYHA class was significantly associated with age
(p = 0.003), pulmonary disease (p = 0.02), mitral valve implant type (p = 0.01), and postoperative stroke (p = 0.02); 14
patients had strokes in the mechanical (9) and in the bioprosthetic (5) groups. NYHA classes were significantly better
after the replacement surgeries (p < 0.001). BMV were significantly associated with worse survival (p = 0.03), worse
NYHA postoperatively (p = 0.01), and more reoperations (p = 0.006). Survival was significantly better with MMV
(p = 0.03). When the two groups were matched for age and mitral regurgitation, the analysis revealed that BMV were
significantly associated with reoperations (p = 0.02) but not significantly associated with worse survival (p = 0.4) or
worse NYHA (p = 0.4).
Conclusion: MMV replacement in mitral stenosis patients is associated with a lower reoperation rate, but there
was no difference in survival compared with BMV replacement.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
MS Mitral Stenosis
BMV Bioprosthetic Mitral Valve
MMV Mechanical Mitral Valve
NYHA New York Heart Association
DM Diabetes Mellitus
HTN Hypertension
CHF Congestive Heart Failure
LV left Ventricle
MR Mitral Regurgitation
EF Ejection Fraction
Op operative
MVR Mitral Valve Replacement
AVR Aortic Valve Replacement
TV Tricuspid Valve
AV Aortic Valve
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MITRAL VALVE REPLACEMENT FOR MITRAL STENOSISIntroduction
Mitral stenosis (MS) is most commonly due torheumatic fever resulting in rheumatic
heart disease [1]. A surgical pathology series of
452 MS patients concluded that 99% of the
patients had postinflammatory disease that was
believed to be rheumatic in origin [2].
Symptomatic MS can be treated by percuta-
neous mitral balloon valvotomy, surgical valvo-
tomy, or surgically replacing the dysfunctional
valve with either a mechanical mitral valve
(MMV) or a bioprosthetic mitral valve (BMV) [3].
Open valvotomy is a repair procedure that
involves direct visualization of the valve and
debridement of the valve structure and recon-
struction of subvalvular apparatus. Mitral valve
replacement is usually preserved for severe MS
that is not fit for percutaneous mitral balloon
valvotomy or valve repair [4].
The purpose of this study was to compare mitral
valve replacement, with either a BMV or a MMV,
in MS patients and evaluate their early survival
and long-term outcome.Materials and methods
Setting and patients
The study was conducted in a tertiary care cardiac
center (King Abdulaziz Cardiac Center) in Riyadh,
Saudi Arabia, and the study population included
all consecutive adult mitral valve replacement
(MVR) patients operated on for mitral valve stenosis
from 1999 to 2012. All patients that fit the inclusion
criteria were enrolled in the study regardless of
their sex and nationality. All the available patients
were included in the study.
Study design
This study is a retrospective cohort of patient
data collected from the center and the follow-up
data gathered by contacting the patients through
the telephone.
Data collection
Eighty variables were collected. They were rep-
resenting information related to demographics,
preoperative underlying conditions, early and late
valve related complications, and pre- and postop-
erative echocardiogram data. Patients’ demo-
graphics, underlying conditions, preoperative
echocardiograms, and early postoperative compli-
cations were obtained from the records of thepatients. Patients’ records were provided as a soft
copy in the form of Excel sheets (Microsoft Corpo-
ration, Redmond, WA, USA), which was then
transferred into SPSS statistical package software
version 20.0 (SPSS Inc., Chicago, IL, USA) for anal-
ysis. Postoperative echocardiogram data were col-
lected using the Picture Archiving and
Communication System to access the echo data-
base. Late follow-up data (long-term) was
acquired by calling the patients’ phone numbers
provided in their hospital records via the hospital
telephone. The patients were called over a period
of 1 month after the data were collected from the
medical records. A total of three calls were made.
The patients who did not respond to the first call
were again contacted after 2 weeks and those
remaining were contacted 1 week after the second
phone call.
A standardized and Institutional Review Board,
King Abdullah international Research Center,
Riyadh approved consent form was used during
telephone calls in gathering the long-term out-
comes information (late follow-up) to collect the
following: (1) late mortality; (2) New York Heart
Association (NYHA) functional class; (3) late
valve-related complications [bleeding (which
required blood transfusion), stroke (embolic or
hemorrhagic), abdominal embolism, and endo-
carditis]; and (4) reoperation.Data management
The patients who underwent MVR were divided
into a BMV group and a MMV group. NYHA
Classes I and II were grouped together as one
group in the analysis, and the same was done
for NYHA Classes III and IV. Ejection fraction
(EF) groups are as follows: (1) normal EF
(P55%); (2) mild left ventricular dysfunction
Table 1. Baseline characteristics of patients.
BMV (n = 50) MMV (n = 145) p
Age (y) 53.7 ± 16.4 46.1 ± 11.5 0.001
Female sex, n (%) 37 (74) 87 (60) 0.08
NYHA pre-opa I & II 14 (31) 39 (33) 0.87
III & IV 31 (69) 81 (68)
Pre-op underlying conditions Smoker 3 (6) 16 (11) 0.30
Obesity 12 (24) 49 (34) 0.20
Hyperlipidemia 17 (34) 39 (27) 0.34
DM 12 (24) 25 (17) 0.29
HTN 13 (26) 24 (17) 0.15
Pulmonary disease 7 (14) 25 (17) 0.59
CHF 19 (38) 36 (25) 0.07
EFb (pre-op) Normal 34 (74) 109 (78) 0.32
Mild LV dysfunction 5 (11) 20 (14)
Moderate to severe LV dysfunction 7 (15) 11 (8)
MS (pre-op) Mild 16 (32) 27 (19) 0.14
Moderate 13 (26) 46 (32)
Severe 21 (42) 72 (50)
MR (pre-op) No regurgitation 4 (8) 28 (19) 0.005
Mild 11 (22) 12 (8)
Moderate 10 (20) 50 (35)
Severe 25 (50) 55 (38)
Data are presented as n (%) or mean ± standard deviation.
BMV = bioprosthetic mitral valve; CHF = chronic heart failure; DM = diabetes mellitus; EF = ejection fraction; HTN = hypertension; LV = left ven-
tricular; MMV = mechanical mitral valve; MR = mitral regurgitation; MS = mitral stenosis; NYHA = New York Heart Association; op = operation.
a New York Heart Association preoperation: BMV = 45, MMV = 120.
b EF: BMV = 46, MMV = 140.
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(<30%) left ventricular dysfunction.Data analysis
Data were entered and analyzed using Microsoft
Excel (Microsoft Corporation) and SPSS version 20
(SPSS Inc.). The categorical variables are pre-
sented as frequencies, percentages, and quantita-
tive variables as mean ± standard deviation.
Chi-square test and logistic regression were used
to compare the categorical variables, and indepen-
dent t test/analysis of variance to compare the
numerical variables. Survival analysis using the
Kaplan–Meier curve was employed. Dependent
proportions test (McNemar test) was used to com-
pare post- and preoperative categorical data. The
primary outcomes were survival and NYHA func-
tional classification. The secondary outcome was
valve-related complications.Results
Baseline characteristics
A total of 195 patients were enrolled in the
study analysis (BMV = 50, MMV = 145). All of
the patients enrolled in the study had theirpostoperative data available up to 30 days post-
operatively in the records. As for the postopera-
tive echocardiogram before discharge of the
patient, five patients’ echo reports were not
available (97.5% available). Regarding telephone
calls, 103 (53%) of the 195 patients responded to
the telephone calls.
The mean age of the patients at operation was
48 ± 13 years. There were 71 (36%) men [BMV
(13) and MMV (58)] and 124 (64%) women [BMV
(37) and MMV (87)]. The follow-up was complete
in 190 patients (97.5%; five patients were lost to
follow-up after discharge from the hospital). The
follow-up period was a minimum of 1 month and
a maximum of 15.5 years with an average of
5.6 ± 4 years of follow-up, a median of 5.2 years,
and a total of 1055 patient years (Table 1). The
patients in the BMV group were older
(53.7 ± 16.4 years vs. 46.1 ± 11.5 years) and had a
bigger proportion of severe MR (50% vs. 38%).
Preoperatively, out of the 195 patients who had
MS: 43 (22%) had mild MS, 59 (30%) had moderate
MS, and 93 (48%) had severe MS.
Mortality
Out of the 195 patients, one patient (0.5%) died
early postoperatively (i.e., <30 days). He was in
36%
83%
64% 17%
0%
20%
40%
60%
80%
100%
NYHA pre-op NYHA post-op
n = 84
III, IV
I, II
p < 0.001
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MITRAL VALVE REPLACEMENT FOR MITRAL STENOSISthe MMV group, and the cause of death was
multiple organ failure. No further analysis in early
mortality was carried out due to the small number
of events. During follow-up, 12 patients died (6 in
the BMV group and 6 in the MMV group). Post-
operatively, both NYHA Classes III and IV (p =
0.002) and occurrence of stroke (p < 0.001) were
found to be significantly associated with late mortal-
ity. NYHA postoperative Classes III and IV were
related to late mortality (p = 0.002). Postoperative
stroke occurrence (embolic or hemorrhagic) was
associated with late mortality (p < 0.001; Table 2).Figure 2. New York Heart Association (NYHA) preoperative and
postoperative. op = operative.Functional class
Postoperatively, 83 (81%) patients were in NYHA
Classes I and II and 20 patients (19%) were in
NYHA Classes III and IV. Postoperative NYHA
class was significantly associated with mitral valve
implant type (p = 0.01) and postoperative stroke
(p = 0.02). BMV was associated with NYHA Classes
III and IV (p = 0.01; Fig. 1).
Logistic regression analysis was used for
postoperative NYHA and preoperative underling
conditions and complications. It revealed that
age (p = 0.003) and pulmonary disease (p = 0.02)
were significantly associated with postoperativeTable 2. Factors associated with late mortality.a
Factors p
NYHA post-op 0.002
Post-op stroke (MMV = 9 & BMV = 5) <0.001
Mitral valve implant type 0.055
Post-op ventricular tachycardia 0.055
BMV = bioprosthetic mitral valve; MMV = mechanical mitral valve;
op = operative.
a Chi-square test.
64%
36%
87%
13%
0%
20%
40%
60%
80%
100%
Class I, II Class III, IV
NYHA post-op
BMV (n = 28) MMV (n = 75)
p = 0.01 
Figure 1. Mitral valve implant type and postoperative New York Heart Association (NYHA). BMV = bioprosthetic mitral valve; op = operative;
MMV = mechanical mitral valve.
Figure 3. Preoperative (pre-op) and postoperative (post-op) ejection
fraction (EF). LV = left ventricular.
Figure 4. Kaplan–Meier survival curve of mitral valve replacement comparing mechanical mitral valves with bioprosthetic mitral valves;
p = 0.03 (Mantel–Cox).
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that postoperative stroke was the only significant
complication (p = 0.04) associated with NYHA
Classes III and IV and mortality.
Analysis of NYHA classes showed significant
difference in proportions (p < 0.001). Most of the
patients who were in NYHA Classes III and IV
preoperatively shifted to Classes I and II postop-
eratively (Fig. 2). However, there was a significant
drop in EF before and after the surgery (p < 0.001;
Fig. 3). Before the surgery 137 (77%) patients had
normal EF, and after the surgery 102 (57%) had
normal EF. These findings might be attributed to
the fact that 84 (43%) patients had MVR, 51
(26%) patients had MVR-tricuspid valve (TV)
repair, 42 (22%) patients had MVR-aortic valve
(AV) replacement, 13 (7%) patients had MVR-A
replacement-TV repair, three (2%) patients had
MVR-TV replacement, one (0.5%) patient had
MVR-AV repair-TV repair, and one (0.5%) patient
had MVR-TV valvectomy. The reduction of the EF
could also be attributed to the fact that most of our
patients had partial subvalvular apparatus
preservation.Complications
Regarding the early complications for the
patients enrolled in the study (n = 195), atrial
fibrillation or flutter, bleeding, and ventricu-
lar tachycardia were the most common earlycomplications. The frequencies are as follows
(n = 104): 19 (18%) patients had bleeding that
required blood transfusion (13 in the MMV group
and 6 in the BMV group), 14 (14%) patients had
strokes (9 in the MMV group and 5 in the BMV
group), 12 (12%) patients died, seven (7%) patients
had reoperations (5 in the BMV group and 2 in the
MMV group), one (1%) patient in the BMV group
had an abdominal embolism, and one (1%) patient
in the MMV group had endocarditis.
BMV versus MMV
MMV had significantly better survival than
BMV (Fig. 4). In the analysis, the following were
significant: MMV was associated with NYHA
postoperative Classes I and II and BMV associated
with NYHA Classes III and IV (Fig. 1); BMV was
associated with reoperations (p = 0.006). BMV
was also associated more with late mortality with
p = 0.055.
When the two groups (BMV and MMV) were
matched for age and mitral regurgitation, the
analysis revealed that BMVs were significantly
associated with reoperations (p = 0.02) but not sig-
nificantly associated with worse survival (p = 0.4)
or worse NYHA (p = 0.4).
Survival
Twelve patients died (6 from BMV and 6 from
MMV). Log rank (Mantel–Cox) test showed that
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MITRAL VALVE REPLACEMENT FOR MITRAL STENOSISthere was a significant difference in survival
between BMV and MMV with p = 0.03. The mean
survival time of BMV is 150.6 ± 12 months
(12.5 years), while MMV had a mean survival of
166 ± 6 months (13.8 years). The mean survival
time of both BMV and MMV is 162 ± 6 months
(13.5 years; Fig. 4). The analysis was carried out
on the two groups (BMV and MMV) that were
case matched for age and mitral regurgitation.
There was no significant difference in survival
(p = 0.4) between the case-matched groups.Discussion
There have been a number of studies comparing
MMVs to BMVs along with recommendations from
the American Heart Association for the manage-
ment of patients with valvular heart disease that
mentioned the advantages and disadvantages for
each of those valve implant types. This study
results matches with the results of previous studies
that were performed to compare BMVs to MMVs.
The Veterans Affairs trial randomized 575
patients to either a MVs or BMVs between 1977
and 1982. After 15 years of follow-up, the study
found that the mortality was similar between the
two groups, primary valve failure was more com-
mon with the BMV group in patients younger than
65 years, reoperations were more common in
BMVs, and a there was a similar rate of valve-
related complication incidences between the two
groups, except for bleeding which was more com-
mon in MMVs [5]. Our study had similar results
except for bleeding which was not significantly
different between the two valve implant types.
In a 2003, a randomized prospective trial per-
formed by Oxenham et al. [6] that involved 261
mitral valve replacements with either a MMV or
a BMV, the survival between the two groups was
similar. The reoperation rate was also higher in
the BMV group. As for the other valve-related
complications, only major bleeding was more
prevalent in the MMV group. But there was no
significant difference in endocarditis or major
embolic events between the two groups. Our
study showed that bleeding was not significantly
different between the two valve types.
Comparable results were found in an observa-
tional study by Ruel et al. [7] that was published
in 2007 that examined the long-term survival out-
comes of heart valve replacement with either a
BMV or a MMV in 567 adults who were younger
than 60 years. They concluded that the survival
in mitral valve replacement is similar between
the two groups, but the reoperation rate was
significantly higher in the BMV group.With regards to perioperative mortality, our
study shows a much lower incidence of early mor-
tality compared with other studies. In our study,
one patient died perioperatively (0.5%) compared
with 4.3% [7], 7.7% [5], and 8.6% [6] in other stud-
ies. These results show us that in this new era,
specialized centers with proper indication for
surgeries can produce extremely good outcomes
with low perioperative mortality, even in the setup
of double and triple valve surgery.
In our study, some results were similar to what
has been found in the literature. The late mortality
was associated more with BMVs. Like the previ-
ous studies, the reoperation rates were also more
common with the BMV group. Moreover, the
other late valve-related complications (abdominal
thromboembolism, stroke, severe bleeding, and
endocarditis) were not significantly different
between the two groups (MMV and BMV), similar
to what has been demonstrated in some of the
previous studies. Postoperative NYHA functional
class analysis showed that the MMV group had
significant association with Classes I and II. To
adjust for the differences in terms of age and
mitral regurgitation between the two groups, case
matching was carried out. Case matching analysis
revealed that BMVs were only significantly associ-
ated with reoperation rates, but not with worse
survival or worse NYHA classes.
There was a significant drop in EF after the sur-
gery. This drop is most likely attributed to two fac-
tors. Firstly, 84 (43%) of our patients had MVR
while the remaining 111 (57%) patients had MVR
plus another valve operation. Secondly, this drop
might be due to the fact that most of our patients
had partial subvalvular apparatus preservation
which has been shown to be associated with lower
EF in comparison to total subvalvular apparatus
preservation in a number of studies. In a prospec-
tive study published in 2010 conducted by Zakai
et al. [8] that included a total of 122 patients, it
was noted that the EF improved in MVR in the
preservation groups compared with the complete
resection group which showed a decline in EF at
follow-up. At the 6th month of follow-up, the
mean EF of Group 1 (complete excision of the sub-
valvular apparatus) was 52.8%, Group 2 (preserva-
tion of the posterior leaflet) had a mean EF of
54.8%, and Group 3 (total chordal preservation)
mean EF was 63.4%. In another retrospective
study published in 2013 conducted by Ghavidel
et al. [9] that included 151 patients, it was
concluded that preserving the mitral annulus
and the papillary muscle continuity may enhance
cardiac performance and lower mortality and
morbidity rates after MVR. A study published in
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compared partial versus complete chordal preser-
vation methods of MVR. The study concluded that
complete retention of the subvalvular apparatus
during MVR in comparison to posterior chordal
preservation resulted in improved ejection perfor-
mance. Many other studies have demonstrated
that subvalvular apparatus preservation is supe-
rior to complete excision in MVR [11–14].
Most of the studies in the literature are compar-
ing MMV and BMV in the setting of both mitral
and TV or mitral regurgitation and MS. Our study
was focused on a specific subgroup of pathology,
which is MS. Furthermore, we were not able to
find a similar study in our region to display what
the data are in relation to the population residing
in this part of the world.
Study limitations
The study design is a retrospective cohort con-
ducted in a single center. Long-term functional
outcome information collection and late complica-
tion data gathering was done using telephone
calls, and 53% of the patients responded at the
time of writing the manuscript.Conclusion
This retrospective cohort study involved 195
patients with MS who underwent MVR with
either BMV or MMV. Late mortality had a signifi-
cant association with postoperative stroke and
postoperative NYHA Classes III and IV. Postoper-
ative NYHA class was significantly associated
with: age, pulmonary disease, and postoperative
stroke. MMV was significantly better in terms of
reoperation rate compared with BMV. Partial
preservation of the subvalvular apparatus in
MVR as opposed to total preservation might lead
to a decrease in the postoperative EF.Acknowledgments
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